Enfu Hui

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 6

Top Topics

Low Density Lipoprotein

Inflammatory Response

Top Venues

The Journal of cell biology

Science (New York, N.Y.)

The Journal of experimental medicine

University of California San Diego

University of Wisconsin Madison (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of California San Diego Jul 01 2016

United States

Assistant Professor :: Cell and Developmental Biology

University of California, San Francisco Jun 16 2010 - Jun 30 2016

United States

Postdoctoral fellow :: Cellular and Molecular Pharmacology

Education History

University of Wisconsin Madison Sep 01 2003 - Aug 23 2009

United States

PHD :: Physiology

Tsinghua University Aug 31 1999 - Jun 30 2003

China

BSC :: Biology

Publications

Xiaozheng Xu, Preston Dennett, Jibin Zhang, Alice Sherrard, Yunlong Zhao, Takeya Masubuchi, Jack D Bui, Xu Chen, Enfu Hui
CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis. The Journal of experimental medicine 220 (7) (2023)
Thiago J Borges, Karina Lima, Ayesha Murshid, Isadora T Lape, Yunlong Zhao, Mauricio Menagatti Rigo, Benjamin J Lang, Shoib S Siddiqui, Enfu Hui, Leonardo V Riella, Cristina Bonorino, Stuart K Calderwood
Innate extracellular Hsp70 inflammatory properties are mediated by the interaction of Siglec-E and LOX-1 receptors. bioRxiv : the preprint server for biology (2023)
Xiaozheng Xu, Takeya Masubuchi, Qixu Cai, Yunlong Zhao, Enfu Hui
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors. eLife 10 (2021)
Enfu Hui
Understanding T cell signaling using membrane reconstitution. Immunological reviews 291 (1) (2020)
Enfu Hui
Immune checkpoint inhibitors. The Journal of cell biology 218 (3) (2019)
Enfu Hui, Jeanne Cheung, Jing Zhu, Xiaolei Su, Marcus J Taylor, Heidi A Wallweber, Dibyendu K Sasmal, Jun Huang, Jeong M Kim, Ira Mellman, Ronald D Vale
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science (New York, N.Y.) 355 (6332) (2017)